Organogenesis acquires NanoMatrix

In addition to acquiring NanoMatrix’s platform technology, intellectual property and commercial-scale equipment, Organogenesis gains NanoMatrix veteran talent, including Gary Cadd, who has already assembled a team within Organogenesis’s R&D department to adapt the technology to the company’s core business.

Geoff MacKay, CEO of Organogenesis, said: “The technology platforms of Organogenesis and NanoMatrix are highly complementary. Our innovative electrospinning techniques enable researchers to develop the most cell-friendly scaffolds and physiologically-realistic tissues to date, translating into greater clinical benefit for the patient.”